A NOVEL ANTIMICROBIAL PLATFORM
A radically different approach for dealing with The worldwide problem of resistance to antibiotics
- Akthelia has developed a new method for fighting infections using new compounds which act by stimulating the production of naturally occurring antimicrobial peptides (AMPs) in the body.
- The antibacterial peptides kill bacteria, including antibiotic-resistant strains.
- Neither the compounds nor the antibacterial peptides cause inflammation.
- The compounds address the problem of infections in general but also those caused by multi drug resistant bacteria.
- Akthelia is targeting Clostridium difficile which is listed as a critical priority pathogen by WHO and identified as an urgent threat level pathogen by the CDC
- In-vitro efficacy has been established against Pseudomonas aeruginosa and resistant Klebsiella pneumoniae with epithelial cells.
- Akthelia’s concept is also applicable to other infections, including infections in veterinary medicine.
- The new compounds can be used alone but also in combination with traditional antibiotics in order to increase efficacy and shorten treatment time.
- Akthelia has filed three patent applications.
Differentiation over existing/competitive approaches and the supporting data
- Our compounds have a different mode of action from traditional antibiotics as they stimulate production of antimicrobial peptides which then kill the bacteria.
- Since the production of multiple antimicrobial factors is induced, the bacteria are unlikely to become resistant. This is in contrast to traditional antibiotics, which act directly on the microbes, thus quickly selecting for resistant strains.